Clinical Trial Update: Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effects of Acetyl-L-carnitine in patients with Mild Cognitive Impairment associated with chronic cerebrovascular disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Acetyl-L-carnitine (N-acetyl-L-carnitine)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Mild Cognitive Impairment | Phase 4 | Status: UNKNOWN